抗癌新药来曲唑的临床进展及市场展望  

Clinical development and future market of novel anticancer drug Letrozole

作　　者：刘爱芹[1] 卢霞[1] 于胜海[1] 

机构地区：[1]山东省医学科学院药物研究所,济南250062

出　　处：《齐鲁药事》2004年第5期37-38,共2页qilu pharmaceutical affairs

摘　　要：通过查阅近几年的文献,综述了来曲唑的药效研究、临床研究的现状。研究结果显示,来曲唑作为新一代非肾上腺皮质类固醇药物,是一种口服的高选择性强效芳香化酶抑制剂。2.5mg来曲唑对晚期乳腺癌的疗效优于标准治疗剂量的氨鲁米特(AG)和甲地孕酮,且毒副作用轻微。Through the pharmacodynamics and clinical studies of Letrozole, a highly selective potent nonsteroidal inhibitor ofaromatase was reviewed. Response rate of Letrozole in 2.5mg was superior to standard dose of Aminogluthimide and Megestrol acetate.Side effects of Letrozole were slight at the same time.

关 键 词：来曲唑 乳腺癌 

分 类 号：R979.1[医药卫生—药品]